Multicentric, Open Label Clinical Trial. Use of Optimal Method to Initiate and Maintain Lantus Therapy (Insulin Glargine) in Combination With Hypoglycemic Agents, Assessing the Resulting Metabolic Control and the Safety in T2 Diabetes Mellitus Patients.

Trial Profile

Multicentric, Open Label Clinical Trial. Use of Optimal Method to Initiate and Maintain Lantus Therapy (Insulin Glargine) in Combination With Hypoglycemic Agents, Assessing the Resulting Metabolic Control and the Safety in T2 Diabetes Mellitus Patients.

Completed
Phase of Trial: Phase IV

Latest Information Update: 09 Feb 2010

At a glance

  • Drugs Antihyperglycaemics; Insulin glargine
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms DOMME
  • Sponsors Sanofi
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 09 Feb 2010 Actual initiation date changed 1 May 2007 to 1 Apr 2007 as reported by ClinicalTrials.gov.
    • 20 Jan 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top